Sivextro

RSS

tedizolid phosphate

Authorised
This medicine is authorised for use in the European Union.

Overview

Sivextro is an antibiotic used in patients from 12 years of age to treat acute (short-term) bacterial infections of the skin and of skin structures (tissue below the skin) such as cellulitis (infection of the skin and the tissue underneath), skin abscesses (a swollen area on the skin where pus has collected) and wound infections.

Before using Sivextro, doctors should consider official guidance on the appropriate use of antibiotics.

Sivextro contains the active substance tedizolid.

This EPAR was last updated on 28/07/2020

Authorisation details

Product details
Name
Sivextro
Agency product number
EMEA/H/C/002846
Active substance
tedizolid phosphate
International non-proprietary name (INN) or common name
tedizolid phosphate
Therapeutic area (MeSH)
  • Soft Tissue Infections
  • Skin Diseases, Bacterial
Anatomical therapeutic chemical (ATC) code
J01
Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
23/03/2015
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

26/06/2020 Sivextro - EMEA/H/C/002846 - II/0035

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Not yet assigned

Therapeutic indication

Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.

Assessment history

How useful was this page?

Add your rating